Whether these T cells, potentially targeting multiple tumor antigens/epitopes, can be expanded to ultimately sustain tumor attack is currently under investigation and will improve our understanding of the full breadth of the CD8+ T cell response generated through prime/boost vaccination and how to best apply such approaches clinically. This evidence concerns the gene CD8A and neoplasm.